이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Khiron Life Sciences 대차 대조표 상태

재무 상태 기준 확인 0/6

Khiron Life Sciences 의 상태를 파악하기에는 데이터가 부족합니다.

주요 정보

n/a

부채 비율

n/a

부채

이자 보상 비율	n/a
현금	n/a
주식	n/a
총 부채	n/a
총 자산	n/a

최근 재무 상태 업데이트

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

May 03

Recent updates

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 17

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Jun 24

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

May 03

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 06

이 섹션에서는 일반적으로 Khiron Life Sciences 의 재무 건전성, 특히 현금 및 부채 수준 관리 능력을 분석하여 재정적 어려움에 얼마나 잘 대비하고 있는지 확인합니다. Khiron Life Sciences 는 적절한 대차 대조표 데이터를 제공하지 않았기 때문에 재무 건전성을 제대로 평가할 수 없습니다.

Simply Wall St에서 다루는 기업의 97%가 재무 정보를 가지고 있기 때문에 이는 매우 드문 상황입니다.

재무 상태 분석

단기부채: KHRN.H 의 단기 자산이 단기 부채를 감당하는지 판단하기에는 데이터가 부족합니다.

장기 부채: KHRN.H 의 단기 자산이 장기 부채를 감당하는지 판단하기에는 데이터가 부족합니다.

부채 대 자본 내역 및 분석

부채 수준: satisfactory인지 판단하기 위해 KHRN.H 의 순 부채 대 자기자본 비율을 계산하기에는 데이터가 부족합니다.

부채 감소: 지난 5년간 KHRN 의 부채비율이 감소했는지 판단하기에는 데이터가 부족합니다.

부채 범위: KHRN.H 의 부채가 영업 현금 흐름에 의해 잘 충당되었는지 판단하기에는 데이터가 부족합니다.

이자 보장: KHRN 의 부채에 대한 이자 지급이 EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.

Khiron Life Sciences 대차 대조표 상태

재무 상태 기준 확인 0/6

주요 정보

최근 재무 상태 업데이트

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

Recent updates

Insufficient new directors

Insufficient new directors

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Khiron Life Sciences Corp. Announces Full Reimbursement by the NHS of Costs Associated to Cannabis-Based Medication and Clinic Fees for A Patient Enrolled in Zerenia Clinics UK

Third quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.019 loss in 3Q 2021)

Khiron Life Sciences Corp. to Report Q3, 2022 Results on Nov 30, 2022

Price target decreased to CA$0.30

Khiron Launches New Cannabis Products in Europe Including Stellar Genetics from California

Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.032 loss in 2Q 2021)

Khiron Life Sciences Corp. to Report Q2, 2022 Results on Aug 29, 2022

Khiron Life Sciences Corp. Announces CFO Changes

Khiron Life Sciences Corp. Announces Resignation of Deborah Rosati from the Board of Directors

Chairman of the Board recently bought CA$150k worth of stock

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 4.01 million.

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.036 loss in 1Q 2021)

Khiron Life Sciences Corp. (TSXV:KHRN) entered into an agreement to acquire Pharmadrug Production GmbH from Pharmadrug Inc. (CNSX:PHRX) for $1.82 Million.

Khiron Life Sciences Corp. to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings released: EPS: CA$0.20 (vs CA$0.20 loss in FY 2020)

Price target decreased to CA$0.87

Khiron Life Sciences Corp., Annual General Meeting, Jun 23, 2022

Khiron Life Sciences Corp. Publishes Clinical Study on the Effectiveness of its Products at Controlling Chronic Pain

No longer forecast to breakeven

Khiron Life Sciences Corp. (TSXV:KHRN) acquired Mcs Clinics Limited for 0.3 million.

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Khiron Life Sciences Corp. Presents Its First Research Study with 1,400 Patients

Second quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.049 loss in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Insider recently sold CA$78k worth of stock

First quarter 2021 earnings released: CA$0.036 loss per share (vs CA$0.079 loss in 1Q 2020)

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

Full year 2020 earnings released: CA$0.20 loss per share (vs CA$0.36 loss in FY 2019)

New 90-day high: CA$0.74

New 90-day high: CA$0.59

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

New 90-day low: CA$0.36

Khiron Life Sciences Corp.'s Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Earnings beat expectations, revenue disappoints

Khiron Life Sciences Corp. Appoints Juan Carlos Echeverry to its Board of Directors

Third quarter 2020 earnings released: CA$0.057 loss per share

Khiron Life Sciences Corp. to Report Q3, 2020 Results on Dec 01, 2020

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 12.6 million.

Earnings beat expectations, revenue disappoints

Second quarter 2020 earnings released: CA$0.049 loss per share

New 90-day low: CA$0.40

Khiron Life Sciences Corp. Announces Changes in Chief Financial Officer

New 90-day low: CA$0.45

Price target raised to CA$1.60

Earnings released

New 90-day low - CA$0.47

Khiron Life Sciences Corp. to Report Q2, 2020 Results on Aug 24, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기